A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at least 30 days. ABOUT ZURA HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura†or the Zura's lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candid ...

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights "I am pleased with the Bio-Techne team's continued execution in a stabilizing operating environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "For the fourth consecutive quarter we delivered double-digit growth in our biggest end market, large pharma. That momentum, together with ...

for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the S ...

Dow Jones Futures Rise After Shift Out Of Tech: AMD, Lumentum Are Earnings Movers | Investor's Business DailyBREAKING: [Dow Futures Rise: AMD, Lumentum Lead Earnings Movers]---Dow Jones futures rose slightly early Wednesday, along with S&P 500 futures. Nasdaq futures were little changed. Nyidia riyal Advanced Micro Devices (AMD) and fellow AI play Lumentum Holdings (LTE) headlined earnings after the close. Eli Lilly (LLY) reports before the open, with Google-parent Alphabet (GOOGL) due after the close. The ...

Core Insights - The company is approaching two major clinical trial efficacy readouts expected in the second quarter of the calendar year [3] Group 1: Clinical Programs - The company is close to announcing results from two different clinical trials [3] Group 2: Corporate Developments - The quarterly webinar is designed to provide updates on clinical programs, corporate developments, and financial position [1][2] - The CEO encourages new investors to visit the company website for additional information [2]

European stocks are seen opening mixed on Wednesday after major U.S. stock averages sold off overnight on fears over AI-led disruption.U.S. equity futures were little changed as investors look ahead to Alphabet earnings later in the day and Amazon earnings due Thursday.Shares of Advanced Micro Devices fell 8 percent in the extended session after the company forecast a slight decline in first-quarter revenue despite an unexpected boost from sales of its AI chips to China.Restaurant owner Chipotle projected ...

As filed with the Securities and Exchange Commission on February 3, 2026. Registration No. 333-293150 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 TO FORM S-1 (State or other jurisdiction of incorporation or organization) Delaware 2834 31-1103425 (Primary Standard Industrial Classification Code Number) (Address, including zip code and telephone number, including area code, of registrant's principal executive offices) Sanjeev Luther President and Chief Executive Off ...

Core Viewpoint - Veradermics has announced the pricing of its upsized initial public offering (IPO) of 15,077,647 shares at $17.00 per share, aiming to raise approximately $256.3 million before expenses [1] Company Overview - Veradermics is a late clinical-stage biopharmaceutical company founded by dermatologists, focusing on innovative therapeutics for aesthetic and dermatological conditions [1] - The company is developing a focused portfolio of aesthetic dermatology product candidates, with a lead program, VDPHL01, targeting pattern hair loss [1] Initial Public Offering Details - The IPO is set to close on February 5, 2026, subject to customary closing conditions, with trading on the New York Stock Exchange expected to begin on February 4, 2026, under the ticker symbol "MANE" [1] - The underwriters have a 30-day option to purchase an additional 2,261,647 shares at the IPO price [1] Product Development - VDPHL01 is being developed as an oral, non-hormonal treatment for pattern hair loss, designed to enhance the effectiveness of minoxidil while minimizing cardiac risks [1] - The company has completed enrollment in its Phase 2/3 clinical trial for VDPHL01 for male pattern hair loss and is actively enrolling women for the first oral treatment trial for female pattern hair loss [2]

February 3, 2026 09:00 PM GMT China Equity Strategy | Asia Pacific Enhancing MSSBT – Capturing Full Alpha From Southbound Eligibility We introduce MSSBT V2, an enhanced forecast model aiming to capture greater alpha generation than V1 by incorporating Southbound deletions, in addition to inclusions. Backtesting shows a 93% hit ratio for our new deletion forecast model and an average 25% absolute return of our two-way trading strategy. Southbound inflows hitting record-highs with prominent impact on the Hong ...

Core Insights - Pharming is presenting its financial guidance for the year and highlighting its clinical stage pipeline programs during the 2026 Investor Day [1][2] - The company has evolved from a single asset company to a fast-growing biotech with two commercial assets experiencing double-digit growth and a late-stage pipeline with two programs each having over $1 billion sales potential [3] Financial Update - A short business and financial update will be provided, focusing on the financial guidance for the year [2] - The company emphasizes its growth trajectory and the potential of its pipeline programs [3] Pipeline Overview - The presentation will include two longer sessions dedicated to the pipeline, specifically on leniolisib for high prevalence primary immunodeficiencies (PIDs) and KL1333, napazimone [2]